Brian C. Stephenson, serving as the Chief Financial Officer for Faeth Therapeutics, Inc. (NASDAQ:FTH), has completed the acquisition of common stock within the company. The total value of the shares purchased amounts to $401,268. According to regulatory filings submitted to the Securities and Exchange Commission, these transactions were executed across two distinct dates: June 24 and June 26, 2026.
Mr. Stephenson acquired a cumulative total of 15,641 shares of Faeth Therapeutics common stock. The execution prices for these shares ranged between $23.61 and $27.77 per share. These purchase prices sit slightly above the stock's current trading level of $23.28. The timing of the acquisition corresponds with a period of pronounced price momentum for the equity. The stock has recorded a 28% return over the preceding week and has delivered a 173% gain over the past twelve months. Additional analysis indicates that the stock has experienced a substantial price uptick over the last six months.
The acquired shares are held indirectly through the Brian Stephenson Revocable Trust. Mr. Stephenson acts as the sole trustee of this trust, retaining sole voting and investment power over the securities. He has disclaimed beneficial ownership of the shares, except to the extent of his pecuniary interest within the trust structure.
In related corporate developments, Sensei Biotherapeutics has initiated a Phase 1b/2 clinical trial for its lead program, PIKTOR. This program targets HR+/HER2- advanced breast cancer. The initiation of this trial follows Sensei's acquisition of Faeth Therapeutics, which resulted in PIKTOR becoming part of Sensei's portfolio.
Analyst coverage has expanded for both entities. Baird has initiated coverage on Faeth Therapeutics with an outperform rating, establishing a price target of $57.00. H.C. Wainwright has also initiated coverage, assigning a buy rating and setting a price target of $60.00. These ratings reflect confidence in Faeth's oncology pipeline. Cantor Fitzgerald has maintained its Overweight rating on Sensei Biotherapeutics, reaffirming this stance following recent investor events. Lucid Capital Markets has started coverage on Sensei Biotherapeutics with a buy rating and a price target of $50.00.
These analyst evaluations underscore market interest in the development of PIKTOR, which Sensei obtained through the acquisition of Faeth Therapeutics. The progression of clinical trials and the issuance of analyst ratings represent significant developments for investors monitoring these organizations.